Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants

？ Ripretinib broadly inhibits primary and drug-resistant KIT/PDGFRA mutants ？ KIT/PDGFRA inhibitor of all known activation loop mutations ？ In drug-resistant cancers, ripretinib blocks kinase signaling and tumor growth ？ Circulating tumor DNA data confirm broad inhibition of mutant KIT in GIST patient